SiBone (NASDAQ:SIBN) Insider Anshul Maheshwari Sells 5,747 Shares of Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 5,747 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $19.55, for a total transaction of $112,353.85. Following the transaction, the insider owned 246,148 shares in the company, valued at approximately $4,812,193.40. This trade represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total value of $87,002.25.
• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The shares were sold at an average price of $16.77, for a total value of $55,626.09.

SiBone Trading Up 2.5%

NASDAQ SIBN opened at $19.96 on Friday. The business’s fifty day moving average is $17.49 and its 200-day moving average is $15.33. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The stock has a market capitalization of $885.23 million, a price-to-earnings ratio of -58.71 and a beta of 0.66. SiBone has a one year low of $11.48 and a one year high of $21.89.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The company had revenue of $56.01 million during the quarter, compared to analyst estimates of $55.34 million. Equities research analysts predict that SiBone will post -0.4 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SIBN. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. TD Cowen lifted their price target on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Truist Financial reiterated a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Finally, UBS Group increased their price objective on SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $24.17.

Institutional Investors Weigh In On SiBone

Institutional investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd bought a new position in SiBone during the fourth quarter worth about $29,000. Versant Capital Management Inc raised its position in shares of SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares during the period. Royal Bank of Canada raised its position in shares of SiBone by 98.5% in the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after purchasing an additional 736 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of SiBone by 64,700.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after buying an additional 1,941 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of SiBone during the 4th quarter valued at approximately $53,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.